DELTASCAN: 1-MINUTE SINGLE-CHANNEL EEG, A VALUABLE TOOL FOR DIAGNOSING DELIRIUM IN FRAIL OLDER PATIENTS IN THE EMERGENCY DEPARTMENT

Loes Caelers, MD[1]; Steffie Peeters, MsC[1]; Laurien Theunissen, MsC[1]; Guy Mostard, MD[2]; Mark Klein Ovink, MD[3]; Maurice Janssen, PhD[4]; Ellen Castro, MD[1]; Chantal de Weerd Spaetgens, MD[1]; Dennis Kurstjens, MD[1]; Audrey Merry, PhD[5]; Walther Sipers, MD, PhD[1]*

[1]Zuyderland Medical Center, Geriatric Medicine

[2]Zuyderland Medical Center, Internal Medicine

[3]Zuyderland Medical Center, Emergency Medicine

[4]Zuyderland Medical Center, Physical Medicine

[5]Zuyderland Medical Center, Zuyderland Academy

* Corresponding author: w.sipers@zuyderland.nl (WS)

https://orcid.org/0000-0003-3031-5735

Abstract

Introduction

Diagnosing delirium is challenging, especially in the emergency department (ED), where up to 80% of

diagnoses are missed. The DeltaScan is a portable EEG-based delirium monitor that makes a single-

channel EEG recording and quantifies delirium on a 5-point scale. The aim of this study was to

determine whether the DeltaScan is an accurate diagnostic instrument for delirium in frail, older

patients that present at the ED.

Method and materials

For this cross-sectional study, data were collected between July 2022 and December 2022 at the ED

of a non-academic teaching hospital in the Netherlands. Patients were included if they were older

than 70 and frail. The included patients underwent the DeltaScan measurement. The results of the

DeltaScan were compared with the results of the Confusion Assessment Method assessed by

delirium experts.

Results

A total of 104 patients were included in this study. The mean age was 84.9 years and 55.4% were

female. Because of technical difficulties 3 patients had to be excluded. There was no diagnostic

consensus between delirium experts in 21 patients. In the remaining 80 patients, delirium was

diagnosed in 41%. The sensitivity of the DeltaScan was 81.3% (67.7-94.8) and the specificity was

89.6% (80.9-98.2). The positive predictive value was 83.9% (70.9-96.8) and the negative predictive

value was 87.8% (78.6-96.9). The area under the receiver operating characteristics curve was 86.5%

(77.5-96.6).

Conclusion

Diagnosing a delirium in frail, older patients attending the ED can be challenging, even for delirium

experts. We demonstrated that DeltaScan measurement is an objective, accurate and feasible

approach to diagnose delirium. We therefore argue that the DeltaScan should have a permanent

place for diagnosing delirium in the ED.

Short title:

DELTASCAN FOR DIAGNOSING DELIRIUM IN THE EMERGENCY DEPARTMENT

Introduction

Diagnosing delirium is challenging, especially in the emergency department (ED), where up to 80% of diagnoses are being missed [1]. One explanation for these missed diagnoses is that diagnostic instruments are subjectively interpreted by means of the clinical observation and the interpretation is therefore highly dependent on the clinical experience of the treating physicians. Physicians that work in the ED are often relatively young with little experience in recognizing delirium and differentiating delirium from dementia and other cognitive disorders. Furthermore, using these diagnostic instruments is time-consuming. Performing the Confusion Assessment Method (CAM) for example, which is the most well studied clinical delirium assessment tool, takes 7 to 15 minutes. *However, even experienced physicians often disagree about the presence or absence of delirium and therefore a high interobserver variability is seen [2].* In the ED, the focus is on acute illness and due to the high turnover there is often limited time to do a full cognitive geriatric assessment. Nevertheless, especially in the ED it is of vital importance that the diagnosis is accurate. Delirium is a signal of an underlying condition. These conditions often present atypically in older people in which delirium may be the only symptom present. Among patients with delirium, the overall mortality rate is increased threefold and is comparable to the mortality rate in patients with myocardial infarction or sepsis [3]. Delay in starting treatment worsens the outcome [4,5].

An objective approach to detect delirium is to monitor physiological changes. During delirium, electroencephalography (EEG) shows a slowdown in background activity, the 'polymorphic delta waves' [6,7,8]. Performing a conventional 25-electrode EEG in all patients at risk for delirium is unsuitable for daily clinical practice because it is burdensome, requires trained personnel for interpretation and is therefore expensive. Previous research showed that delirium could be adequately assessed using a single channel EEG looking at delta waves [9]. A proof-of-concept study with 28 postoperative cardiothoracic patients showed that the relative deltapower of a one-minute EEG recording with only two electrodes can distinguish between patients who have delirium and

those who do not [10]. Based on these findings, Ditzel et al. developed and validated the DeltaScan

algorithm in a study with 145 patients who underwent major surgery [11]. This study showed a

diagnostic performance of >85% (AUC=0.86, CI = [0.81–0.90]). To improve the feasibility of the

measurement of the DeltaScan algorithm, the DeltaScan was developed (Prolira® Arnhem, the

Netherlands). The DeltaScan is a portable EEG-based delirium monitor that makes a single-channel

EEG recording in 1 minute. Based on this EEG recording the DeltaScan quantifies delirium on a 5-

point scale.

However, the diagnostic performance of the DeltaScan has not yet been investigated in patients in

the ED. Furthermore, the DeltaScan has not been validated in patients with cognitive disorders such

as dementia. Patients presenting at the ED with a possible delirium are a heterogeneous group with

various acute illnesses and comorbidities such as dementia are frequent. They are generally older,

frail and polypharmacy is common in this population.

The aim of this study was to determine whether the DeltaScan is an accurate diagnostic instrument

for delirium in frail, older patients with and without cognitive disorders that present at the ED.

Furthermore, we aimed to determine whether the DeltaScan is time efficient and feasible in patients

with possible cognitive disorders and agitation that might complicate the DeltaScan measurement.

We hypothesize that the DeltaScan is a feasible, fast, and accurate diagnostic instrument not only in

well-defined study cohorts but also in a heterogeneous, older, and frail population.

Methods

Study setting and population

This cross-sectional study was done in a non-academic teaching hospital in the Netherlands. The data were collected at the ED between July 2022 and December 2022. Patients were included if they were older than 70 years, frail according to the Groningen Frailty Indicator (GFI, frail if score ≥4) or according to the Identification of the Seniors At Risk (ISAR, frail if score ≥2) and if they were referred to the ED for the specialties geriatric medicine, internal medicine or emergency medicine. Patients were excluded if they were terminally ill, if it was impossible to take cognitive tests due to deafness or a language barrier, if head bandage prevented the placement of electrodes, if they used lithium or clozapine, if macro brain injury during the 6 weeks before referral to the ED had occurred or if they had a metal plate or device in cerebro. Patients were also excluded if severe agitation interfered with the DeltaScan measurement. Informed consent was obtained from all participants or their legal representatives.

Data collection and classification

The two researchers, SP and LT, which are medical students in the final master phase, included patients at the ED that met the inclusion criteria. Of the included patients, patient characteristics were recorded on the patient report file (PRF), including referral information, patient history, anamnesis, hetero anamnesis, and additional research that was done in the ED like laboratory diagnostics, electrocardiogram and imaging.

For this study we used the Prolira® (Arnhem, The Netherlands) DeltaScan Brain State Monitor (serial number: 20050009, algorithm version 2.4.2, DeltScan Patch version: REF 009.000.B, Lavel V2B). The DeltaScan is an EEG-based delirium monitor that makes a single-channel EEG recording in one minute using three electrodes. The DeltaScan quantifies a delirium on a 5-point scale. Score 1 means very unlikely delirium, 2 unlikely delirium, 3 possible delirium, 4 likely delirium and 5 means very likely

delirium. We categorized a DeltaScan score of 1 or 2 as no delirium and a score of 3, 4, or 5 as

delirium.

The two researchers were trained by an expert researcher affiliated with Prolira® to use the

DeltaScan equipment. The expert supervised the first measurements and was available for

troubleshooting in case of device-related questions or problems. The researchers visited the included

patients at the ED to perform a cognitive assessment based on the CAM, which was recorded on

video. Immediately after the cognitive assessment, the DeltaScan measurement was performed.

Since noise, such as eye movements and glossokinetic artifacts predominantly manifests within the

low-frequency range of the DeltaScan, the researcher ensured that during the 1-minute recording

the patients had their eyes closed and did not speak.

The videos were assessed by the delirium experts if the score of the DeltaScan was 2, 3 or 4, or if

there was no consensus about the presence or absence of delirium between the ED resident, the

attending geriatrician, and the researcher. If the score of the DeltaScan was 1 or 5, and there was

consensus between the ED resident, the attending geriatrician and the researcher, the diagnosis was

confirmed, and no further video assessment was done. The delirium experts were two independent

geriatricians with at least 8 years of experience. They were blinded from the DeltaScan score and the

conclusion of the researcher, ED resident and attending geriatrician. After examining the PRF and the

videos they classified diagnosis based on the CAM criteria (gold standard) in the following five

options: 1) clinical picture of a delirium with features of a delirium at that moment, with actual at

least 3 positive CAM criteria, 2) clinical picture of a delirium with some delirious features at that

moment, with at least 1 actual CAM criterium, 3) clinical picture of a delirium with doubtful delirious

features at that moment, without an actual CAM criterium, however with clinical information high

suspicious for a delirium, 4) possible delirium, with clinical information with some hallmarks of a

delirium 5) no delirium. We categorized a score of 1-4 as delirium and a score of 5 as no delirium

according the CAM criteria. If there was an agreement between the two delirium experts, the

conclusion was added to the results. Patients were not included in the analysis if there was no

agreement between the delirium experts due to uncertainty about the diagnosis.

Outcome measures

The primary outcome of our study was the diagnostic value of the DeltaScan in terms of sensitivity,

specificity, positive predictive value (PPV), negative predicting value (NPV), receiver operating

characteristic curve (ROC curve) and area under the ROC Curve (AUC), using the diagnosis made by

the independent delirium experts based on the CAM criteria as 'gold standard'. Furthermore, we

wanted to determine the feasibility of the DeltaScan by measuring the number of patients that were

excluded due to technical difficulties and severe agitation that interfered with the DeltaScan

measurement.

Sample size calculation

151 We did not perform a power analysis in advance because due to financial reasons there were 110

152 electrode-patches available.

Statistical analysis

Analysis was performed in SPSS (SPSS Statistics, version 26). Categorical variables were presented as

numbers with the corresponding percentages, continuous variables were presented as mean with

Standard Deviation (SD) (normal distribution).

Differences between the patients with a positive DeltaScan score and a negative DeltaScan score

were determined by means of the Chi-square test and the Fisher-Freeman-Halton exact test for

categorical variables. The independent sample-t-test was applied to compare continuous variables

with a normal distribution. If not normally distributed, the Mann-Whitney U test was used. Receiver

operating characteristics (ROC) curve was computed and the area under the ROC curve (AUC) was

calculated with accompanying 95% confidence interval (CI). In addition, we calculated the PPV, NPV,

sensitivity, and specificity for the DeltaScan scores/diagnoses using the diagnoses made by the

delirium experts as reference. Feasibility was determined by evaluating the number of patients

excluded due to technical failure of the DeltaScan and due to severe agitation that interfered with

the DeltaScan measurement. Also, the time it took to learn how to use the DeltaScan and the time

consumption of the DeltaScan measurement were considered.

The study was approved by the Medical Ethics Committee of Zuyderland and Zuyd University of

Applied Sciences (protocol METCZ20220008).

Results

Study population

Figure 1 shows the trial profile of the research population. Initially, 104 patients met the inclusion

criteria. Due to technical difficulties with the DeltaScan, 3 patients were excluded. No patients were

excluded due to severe agitation that interfered with the DeltaScan measurement. Of the 101

patients that were initially assessed, the DeltaScan score was 1 or 5 in 65 cases (64.4%). In 47 of

these cases, there was consensus about the diagnosis between the ED resident, the attending

geriatrician and the researcher and the videos were not assessed by the delirium experts. In the

remaining 18 cases in which there was no consensus about the diagnosis, and in the 36 cases in

which the DeltaScan score was 2, 3 or 4, the videos were assessed by the delirium experts. In 33 of

these 54 cases, there was consensus between the 2 delirium experts about the presence or absence

of delirium. This resulted in a definite conclusion in 80 patients.

Baseline characteristics

Supplementary Table 1 shows the baseline characteristics of the included patients (n=101) and the

patients with consensus about the diagnosis of delirium according to reference (n=80). The mean age

was 84.9 years and 55.4% were female of the included patients. A history of cerebrovascular

accidents was found in 29.7% and a history of delirium was found in 16.8% of the patients. Dementia

occurred in 22.8% of the patients. Psychopharmaceutic drugs were used by 35.6% of the patients; in

9.9% benzodiazepines were used. These characteristics did not differ significantly for the patients

with (n=80) and without diagnostic consensus (n=21). Also, there were no significant differences

between the patients with and without delirium according to the DeltaScan (*Table 1*).

Outcome

Table 2 shows an overview of the results of the DeltaScan compared to the reference. There were 26

patients with a positive score on the DeltaScan (score 3,4 or 5) and a positive diagnosis according to

the CAM criteria, 5 patients with a positive result on the DeltaScan and a negative diagnosis

according to the CAM criteria, 7 patients with a negative result on the DeltaScan (score 1 or 2) and a

positive diagnosis according to the CAM criteria and 42 patients with a negative result on the

DeltaScan and a negative diagnosis according to the CAM criteria. Sensitivity was 81.3% (CI 67.7%-

94.8%) and specificity was 89.6% (CI 80.9%-98.2%). PPV was 83.9% (CI 70.9%-96.8%) and NPV was

87.8% (CI 78.6%-96.9%). Figure 2 shows the ROC curve of the diagnostic value of the DeltaScan

compared to the reference. The area under the ROC curve (AUC) is 86.5% (CI 77.5%-95.6%).

Table 3 presents an overview of the individual DeltaScan scores versus the individual classifications

according to the assessments of the delirium experts. In case of a delirium diagnosis according to the

reference in the presence of delirium features on the moment of measurement, DeltaScan score is

positive in 21 of 23 patients (91%). In case of a delirium diagnosis according to the reference in

absence of delirium features on the moment of measurement, DeltaScan score is positive in 1 of 4

patients (25%).

The time it took to learn how to use the DeltaScan was less than 1 hour. The time consumption of the

DeltaScan measurement was 5 minutes. None of the patients had to be excluded due to severe

agitation that complicated the DeltaScan measurement.

Figure 1

Table 1 Comparison of baseline characteristics of the patients with a positive (n=31) and negative
result (n=49) on the DeltaScan (n=80)
214

216 *Table 2 Results of DeltaScan score compared with diagnosis delirium according with CAM criteria with*
217 *consensus reference in frail older patients (n=80) in the ED*
218
219
220
221 *Table 3 Overview of frail older patients (n=80) in the ED with individual DeltaScan scores versus*
222 *individual groups reference diagnosis according CAM criteria*

223
224
225

226 *Figure 2 ROC curve of the DeltaScan in diagnosing delirium according CAM criteria in frail older*

227 *patients (n=80) in the ED*

Discussion

The aim of this study was to determine whether the DeltaScan is a feasible and accurate diagnostic

instrument for delirium in frail, older patients with and without cognitive disorders attending the ED.

Diagnosing delirium can be challenging and therefore diagnoses are often missed.

We included 101 patients (mean age 84.9 years) from which 22.8% had dementia. The results of the

DeltaScan were compared with the results of the Confusion Assessment Method based on consensus

between researchers and attending physician or delirium experts. Our study demonstrates that the

DeltaScan is a feasible and accurate instrument for diagnosing delirium in frail, older patients at the

ED. Even though 3% (3/104) of the patients had to be excluded due to technical difficulties of the

DeltaScan, none of the patients had to be excluded due to severe agitation that complicated the

DeltaScan measurement. Also, performing the DeltaScan measurement took only 5 minutes. This

shows that the DeltaScan is a feasible instrument, even when patients have cognitive disorders in

which case they might not be able to understand instructions. The technical difficulties occurred

early in the study and were caused by an outdated version of the electrode-patches. During the

study, the electrodes were replaced by a new series and no further technical problems occurred.

Furthermore, our study demonstrates that the DeltaScan is an accurate diagnostic instrument, with a

sensitivity of 81.3% (CI 67.7%-94.8%) and a specificity of 89.6% (CI 80.9%-98.2%). The PPV was 83.9%

(CI 70.9%-96.8%) and the NPV was 87.8% (CI 78.6%-96.9%). The AUC was 86.5% (CI 77.5-95.6).

Our findings confirm the assumptions of previous studies, which found comparable diagnostic values

of the DeltaScan in well-selected patients and confined study environments [9,11,12]. There are

several differences between previous studies and the present study. Most importantly, previous

studies were done in well-defined study cohorts while the present study was done in a

heterogenous, frail, older population in the ED. In contrast to our study, in previous research

populations patients with cognitive disorders or dementia were either excluded [10,13] or not likely

prevalent due to relatively young research populations that had underwent major surgery or were

admitted to the ICU [2,9,11,12,14], both interventions that are generally too invasive in frail patients

with cognitive disorders or dementia. There are several distinct diseases that are classified under the

umbrella term 'dementia', and they have different, specific electroencephalogram characteristics.

Overall, typical findings in the various types of dementia are an increase in EEG slow wave activity,

e.g. theta and delta frequencies, together with decreased activity in the alpha frequency [14]. The

study was not primarily designed to investigate the diagnostic performance of the DeltaScan in

patients with dementia, therefore we cannot make any further statements about this. We simply

choose not to exclude patients with a dementia to make our results more generalizable to daily

practice because of the high prevalence of cognitive disorders and dementia in frail, older patients

that present at the ED [15,16]. Moreover, especially in case of cognitive disorders, diagnosing

delirium can be challenging due to overlap in symptoms and clinical presentation, which emphasizes

the need for a better diagnostic instrument in this patient group. Also, in many cases, dementia is not

recognized and diagnosed late [17], which means that a possible diagnosis of dementia is not always

known at the time of presentation at the ED and therefore exclusion is not always possible.

Diagnosing delirium in the ED by using the DeltaScan is objective and time efficient. Moreover,

specific expertise in recognizing and diagnosing delirium is not required. In our study, the two

researchers were trained both theoretically and practically by an expert researcher affiliated with

Prolira® to use the DeltaScan equipment, which took only 60 minutes in total. After that, they were

able to perform the entire measurement on their own in 5 minutes. Furthermore, no background

knowledge about the EEG and its interpretation is required because the DeltaScan contains an

independently functioning algorithm. Our findings suggest that this is an approach that could be used

to diagnose delirium by bedside nurses at the ED as part of the clinical routine, especially at the ED

setting where nurses already monitor a broad range of information. Since delirium is frequently

missed in the ED, the DeltaScan can make an important contribution to the improvement of the

quality of care for frail, older patients in the ED.

Clearly, there are limitations of the present study. One of the main difficulties when investigating a

diagnostic instrument for delirium is the lack of a flawless gold standard. Studies on delirium

detection tools usually have a delirium expert or a panel of delirium experts as reference. However,

experts frequently disagree about the diagnosis of delirium, even when considering the same clinical

and cognitive information [2]. Even though delirium experts involved in our study had extensive

experience in diagnosing delirium, there was no consensus when applying the CAM criteria between

the experts in 21% of the cases. In previous research this number was lower (Numan 2018). In our

opinion the lack of a perfect gold standard and the level of disagreement between delirium experts

only emphasize the need for an objective instrument like the DeltaScan. To overcome this problem

in patients with altered behavior and a low score on the DeltaScan, one or more follow-up

measurements should be considered to be certain whether this low score is caused by a fluctuation

in the condition and to be certain of a correct diagnosis. However, this should be investigated

further.

Furthermore, EEG recordings were performed only once, which might have resulted in overlooking

periods of slowing of the EEG. One of the key features of delirium is its fluctuating course. It is a

possibility that the DeltaScan score is influenced by the presence or absence of delirium features at

the time of the measurement. This might explain that, as can be seen in table 3, in case of delirium

according to the reference, DeltaScan score is positive in 21/23 (91.3%) patients with delirium with at

least 3 CAM criteria, in contrast to 1/4 (25%) patients with delirium without delirium features at that

moment. Therefore, in patients with persistent behavioral changes, a repeat of the DeltaScan

measurement seems appropriate. For clinical practice, as suggested above, a diagnostic algorithm in

applying the DeltaScan could be of value.

Finally, it could be argued that the observed differences in EEG characteristics between patients

classified with or without delirium were influenced by differences in drowsiness, sleep or

administration of benzodiazepines or opioids. Furthermore, noise, such as eye movements and

glossokinetic artifacts, predominantly manifests within the low-frequency range of the EEG and can

therefore influence the DeltaScan measurement. However, use of psychotropic drugs,

benzodiazepines and opiates did not differ between the patients with a positive DeltaScan score and

the patients with a negative DeltaScan score. In addition, polymorphic delta activity caused by sleep

or noise seems unlikely since the researcher constantly ensured that the patients were awake, had

their eyes closed and did not speak during the measurement.

Conclusion

Diagnosing a delirium in frail, older patients that present at the ED can be challenging, even for

delirium experts. The present study demonstrated that DeltaScan measurement is an objective,

accurate and feasible approach to diagnose delirium in these patients in the ED. We therefore argue

that the DeltaScan should have a permanent place for diagnosing delirium in the ED.

316 Acknowledgments

317 In addition to the authors, we thank Erik Tio, clinical specialist DeltaScan from Prolira for training our

318 researchers and his availability for troubleshooting in case of device-related questions or problems

References

1. Lewis LM, Miller DK, Morley JE, Nork MJ, Lasater LC. Unrecognized delirium in ED geriatric patients. Am J Emerg Med 1995; 13: 142–5.

2. Numan T, van den Boogaard M, Kamper AM *et al.* Recognition of Delirium in Postoperative Elderly Patients: A Multicenter Study. J Am Geriatr Soc 2017; 65: 1932–1938.

3. Ely EW, Shintani A, Truman B *et al.* Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004; 291: 1753–62.

4. Marcantonio ER. Delirium in Hospitalized Older Adults. N Engl J Med 2017; 377: 1456–1466.

5. Slooter AJC, Van De Leur RR, Zaal IJ. Delirium in critically ill patients. Handb Clin Neurol 2017; 141: 449–466.

6. Koponen H, Partanen J, Pääkkönen A, Mattila E, Riekkinen PJ. EEG spectral analysis in delirium. J Neurol Neurosurg Psychiatry 1989; 52: 980–5.

7. Hut SCA, Dijkstra-Kersten SMA, Numan T *et al.* EEG and clinical assessment in delirium and acute encephalopathy. Psychiatry Clin Neurosci 2021; 75: 265–266.

8. Pandharipande PP, Ely EW, Arora RC *et al.* The intensive care delirium research agenda: a multinational, interprofessional perspective. Intensive Care Medicine 43 2017 1329–1339.

9. Numan T, van den Boogaard M, Kamper AM *et al.* Delirium detection using relative delta power based on 1-minute single-channel EEG: a multicentre study. Br J Anaesth 2019; 122: 60–68.

10. van der Kooi AW, Zaal IJ, Klijn FA *et al.* Delirium detection using EEG: what and how to measure. Chest 2015; 147: 94–101.

11. Ditzel FL, Hut SC, Dijkstra-Kersten SM *et al.* An automated electroencephalography algorithm to detect polymorphic delta activity in acute encephalopathy presenting as postoperative delirium. Psychiatry Clin Neurosci 2022; 76: 676–678.

12. Aben J, Pouwels S, Oldenbeuving A. Comparison Between Deltascan Single Channel Electroencephalography (EEG), Confusion Assessment Method-Intensive Care Unit (CAM-ICU) Score and Clinical Assessment in Diagnosing Delirium in Intubated Patients in the Intensive Care Unit. Cureus 2022; 14: e26449.

13. Hut SCA, Dijkstra-Kersten SMA, Numan T *et al.* EEG and clinical assessment in delirium and acute encephalopathy. Psychiatry Clin Neurosci 2021; 75: 265–266.

14. Malek N, Baker MR, Mann C, Greene J. Electroencephalographic markers in dementia. Acta Neurologica Scandinavica 135 2017 388–393.

15. Hirschman KB, Paik HH, Pines JM, McCusker CM, Naylor MD, Hollander JE. Cognitive Impairment among Older Adults in the Emergency Department. West J Emerg Med 2011; 12: 56–62.

16. LaMantia MA, Stump TE, Messina FC, Miller DK, Callahan CM. Emergency Department Use Among Older Adults With Dementia. Alzheimer Dis Assoc Disord 2016; 30: 35–40.

17. Amjad H, Roth DL, Sheehan OC, Lyketsos CG, Wolff JL, Samus QM. Underdiagnosis of Dementia: an Observational Study of Patterns in Diagnosis and Awareness in US Older Adults. J Gen Intern Med 2018; 33: 1131–1138.

Figure 1 Flowchart of inclusion of frail older patients at the ER in diagnosing delirium. Score 1-5 means CAM score: 1) clinical picture of a delirium with features of a delirium at that moment, with actual at least 3 positive CAM criteria, 2) clinical picture of a delirium with some delirious features at that moment, with at least 1 actual CAM criterium, 3) clinical picture of a delirium with doubtful delirious features at that moment, without an actual CAM criterium, however with clinical information high suspicious for a delirium, 4) possible delirium, with clinical information with some hallmarks of a delirium 5) no delirium.

Figure 2 ROC curve of the DeltaScan in diagnosing delirium according CAM criteria in frail older patients (n=80) in the ED . AUC of 86.5% (95% CI 77.5-95.6)

Table 1 Comparison of baseline characteristics of the patients with a positive (n=31) and negative result (n=49) on the DeltaScan (n=80)

	NEGATIVE RESULT DELTASCAN (SCORE 1-2) (N=49)	POSITIVE RESULT DELTASCAN (SCORE 3-4-5) (N = 31)	P-VALUE
AGE	85.5 ± 2.9	83.5 ± 7.1	0.132[a]*
			0.309[b]*
GENDER			0.661[c]
- MALE	23 (46.9%)	13 (41.9%)	
- FEMALE	26 (53.1%)	18 (58.1%)	
HISTORY			
- CEREBROVASCULAIR ACCIDENT	17 (34.7%)	7 (22.6%)	0.249[c]
- DEMENTIA	7 (14.3%)	11 (35.5%)	0.027[c]
- MILD COGNITIVE IMPAIRMENT	4 (8.2%)	1 (3.2%)	0.606[d]
- PARKINSON'S DISEASE	1 (2.0%)	4 (12.9%)	0.104[d]
- EPILEPSY	0 (0%)	1 (3.2%)	0.387[d]
- TUMOR MALIGNANCY BRAIN	0 (0%)	1 (3.2%)	0.387[d]
- DELIRIUM	8 (16.3%)	5 (16.1%)	0.981[c]
- DEPRESSION	3 (6.1%)	3 (9.7%)	0.672[d]
- ANXIETY DISORDER	2 (4.1%)	3 (9.7%)	0.370[d]
- SUBSTANCE ABUSE	5 (10.2%)	2 (6.5%)	0.700[d]
USE OF PSYCHOTROPHIC DRUGS	16 (32.7%)	11 (35.5%)	0.794[c]
- BENZODIAZEPINE	4 (8.2%)	3 (9.7%)	
USE OF OPIOATES	6 (12.2%)	6 (19.4%)	0.522[d]
CHARLSON COMORBIDITY INDEX	2.7 ± 2.1	2.9 ± 2.5	0.880[b]

Data are reported as mean (SD) or number (%)

Table 2 Results of DeltaScan score compared with diagnosis delirium according with CAM criteria with consensus reference in frail older patients (n=80) in the ED

	DELIRIUM ACCORDING TO THE CAM CRITERIA	NO DELIRIUM ACCORDING TO THE CAM CRITERIA	TOTAL
POSITIVE SCORE DELTASCAN (3,4,5)	26	5	31
NEGATIVE SCORE DELTASCAN (1,2)	7	42	49
TOTAL	33	47	80

Sensitivity 81.3% (CI 67.7%-94.8%)
Specificity 89.6% (CI 80.9%-98.2%)
PPV 83.9% (CI 70.9%-96.8%)
NPV 87.8% (CI 78.6%-96.9%)

Table 3 Overview of frail older patients (n=80) in the ED with individual DeltaScan scores versus individual groups reference diagnosis according CAM criteria

	RESULT REFERENCE ACORDING CAM CRITERIA					TOTAL PATIENTS
SCORE DELTASCAN	No delirium[5]	Delirium + features[1]	Delirium − features[2]	Delirium +/- features[3]	Doubtful delirium[4]	
1	41	2	3	0	0	46
2	1	0	0	1	1	3
3	2	5	1	1	1	10
4	1	7	0	1	1	10
5	2	9	0	0	0	11
TOTAL PATIENTS	47	23	4	3	3	80

[5] No delirium diagnosis, also no features of delirium present. [1] Delirium diagnosis with features of a delirium at that moment, with actual at least 3 positive CAM criteria. [2] Delirium diagnosis with some delirious features at that moment, with at least 1 actual CAM criterium. [3] Delirium diagnosis with doubtful delirious features at that moment, without an actual CAM criterium, however with clinical information high suspicious for a delirium.[4] Doubtful delirium diagnosis, with clinical information with some hallmarks of a delirium

Supplementary Table 1 Baseline characteristics of the frail older patients in the ED

	N= 80	N=101
AGE	84.8 ± 5.0	84.9 ± 5.0
GFI	5 ± 2.9	6 ± 2.8
GENDER		
- **MALE**	36 (45.0%)	45 (44.6%)
- **FEMALE**	44 (55.0%)	56 (55.4%)
HISTORY		
- **CEREBROVASCULAIR ACCIDENT**	24 (30.0%)	30 (29.7%)
- **DEMENTIA**		
- **MILD COGNITIVE IMPAIRMENT**	18 (22.5%)	23 (22.8%)
- **PARKINSON'S DISEASE**	5 (6.3%)	6 (5.9%)
- **EPILEPSY**		
- **TUMOR MALIGNANCY BRAIN**	5 (6.3%)	6 (5.9%)
- **DELIRIUM**	1 (1.3%)	1 (1.0%)
- **DEPRESSION**	1 (1.3%)	1 (1.0%)
- **ANXIETY DISORDER**		
- **SUBSTANCE ABUSE**	13 (16.3%)	17 (16.8%)
	6 (7.5%)	8 (7.9%)
	5 (6.3%)	6 (5.9%)
	7 (8.8%)	7 (6.9%)
USE OF PSYCHOPHARMACA	27 (33.8%)	36 (35.6%)
- **OF WICH BENZODIAZPINES**	7 (8.8%)	10 (9.9%)
USE OF OPIOATES	12 (15.0%)	16 (15.8%)
CHARLSON COMORBIDITY INDEX	2.8 ± 2.3	2.7 ± 2.1